Net Income (Continuing Operations) indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Orgenesis's net income (continuing operations) for the
three
months ended in Dec. 2021 was $-5.02 Mil. Its net income (continuing operations) for the trailing twelve months (TTM) ended in Dec. 2021 was $-18.06 Mil.
Orgenesis Net Income (Continuing Operations) Calculation
It indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period.
Net Income (Continuing Operations) for the trailing twelve months (TTM) ended in Dec. 2021 adds up the quarterly data reported by the company within the most recent 12 months, which was $-18.06 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Orgenesis (NAS:ORGS) Net Income (Continuing Operations) Explanation
Net Income (Continuing Operations) excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.
Orgenesis Business Description
Traded in Other Exchanges
Address
20271 Goldenrod Lane, Germantown, MD, USA, 20876
Orgenesis Inc is a part of the healthcare sector. It is a fully-integrated biopharmaceutical company focused on developing trans-differentiation technologies for diabetes and vertically integrating manufacturing that can optimize its abilities to scale-up its technologies for clinical trials and eventual commercialization. The group operates in two segments namely CDMO and POC. The company is also engaged in applying its disciplined execution to emerging technologies of other cell therapy markets in such areas as cell-based cancer immunotherapies and neurodegenerative diseases.
Executives
| Sidransky David |
director |
JOHNS HOPKINS UNIVERSITY 720 RUTLAND AVENUE BALTIMORE MD 21205 |
| Reithinger Neil |
officer: CFO, Treasurer and Secretary |
14950 N. 83RD PLACE SUITE 1 SCOTTSDALE AZ 85260 |
| Philips Mario |
director |
C/O ATMI, INC DANBURY CT 06810 |
| Ferber Sarah |
officer: Chief Scientific Officer |
17B HAHASKALA STREET TEL AVIV L3 67890 |
| Yachin Guy |
director |
7 ORCHARD WAY N POTOMAC MD 20854 |
| Nanda Ashish |
director |
2301, 23RD FLOOR, TIFFANY TOWERS CLUSTER W, JLT, DUBAI, UAE DUBAI C0 4452 |
| Bedoret Denis |
officer: See Remarks |
48, RUE AUGUSTE PICCARD GOSSELIES C9 6041 |
| Universite Libre De Bruxelles |
other: less than 10% |
AVENUE F, ROOSEVELT, 50 BRUSSELS C9 1050 |
| Theodorus Ii Sa |
other: less than 10% |
ALLEE DE LA RECHERCHE, 12 BRUSSELS C9 1070 |
| Theodorus Sca |
other: less than 10% |
ALLEE DE LA RECHERCHE, 12 BRUSSELS C9 1070 |
| Belenger Olivier |
other: less than 10% |
DIEWEG, 69 BRUSSELS C9 1070 |
| Shvartz Oded |
10 percent owner |
130 BIRUINTEI BVD. PANTELIMON, ILFOV S5 0000000 |
| Bultot Hugues |
director |
AVENUE DE L??HORIZON 24 WOLUWE SAINT PIERRE C9 1150 |
| Buyse Chris Georges Frans |
director |
BAILLET LATOURLEI 119A BRUSSELS C9 2390 |
| Tenne Joseph |
officer: CFO Treasurer Secretary |
6225 NEIL ROAD, SUITE 300 C/O ORMAT TECHNOLOGIES, INC. RENO NV 89511 |
Orgenesis Headlines
By Seekingalpha 2021-05-17
By Seekingalpha 2021-01-28
By Seekingalpha 2021-11-06
My Portfolios
Create New Portfolio
Portfolio Contest
My Gurus
Personalize
Premium Gurus 
0.03(1.45%) Volume: 10,448 11:35AM EDT
Email Alerts
Stock PDF
RSS
Website
Filings
Download
Manual of Stocks™ Web APP
NAS:ORGS has been successfully added to your 
